Rethinking transparency and accountability in medicines regulation in the United Kingdom

British Medical Journal

Volumn 318, Issue 7175, 1999, Pages 46-47

  Abraham, John ^a,b   Sheppard, Julie ^a,b   Reed, Tim ^a,b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b Consumers' Association ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; GOVERNMENT; LICENSING; MEDICOLEGAL ASPECT; PRIORITY JOURNAL; PROFESSIONAL SECRECY; PUBLIC HEALTH; SHORT SURVEY; UNITED KINGDOM;

EID: 0033513981     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7175.46     Document Type: Short Survey

References (11)

1. 1 Home Secretary. Open government. London: HMSO, 1993:49. (Cm 2290.)
2. 2 MP seeks to lift veil of drug secrecy. BMJ 1993;303:84.
3. 3 Medicines information bill clears first hurdle. Scrip 1993;1788:5.
4. 4 UK medicines information bill blocked. Scrip 1993;1818/19:2.
5. 5 UK health secretary on transparency. Scrip 1993;1866:4.
6. 6 Dr John Griffin takes over as ABPI chief. ABPI News 1984;198:1.
7. 7 New ABPI director stresses importance of two-way flow between medicines division and industry. ABPI News 1984;198:3.
8. 8 Delamothe T. Drug watchdogs and the drug industry. BMJ 1989;299:476.
9. 9 Medicines Control Agency. Annual report for 1996. London: Medicines Control Agency, 1997.
10. 10 Abraham J. Science, politics and the pharmaceutical industry. London: University College London/St Martins Press, 1995.
11. 11 Royal Courts of Justice. Judgement between the Upjohn Company and Upjohn Ltd and Professor Ian Oswald and between Dr Royston Frederick Drucker and Professor Oswald and between the Upjohn Company and Upjohn Ltd and the BBC and Tom Mangold before Mr Justice May, Beverley F. London: Nunnery, 1994.